Three weeks is early, so give it time and follow the recommended escalation schedule, you haven't reached a therapeutic dose yet. The trials show some low responders, but they're clearly a minority, and retatrutide looks like the strongest obesity drug so far for most people. I also think the trial numbers undersell what happens at the higher doses. Several participants have said online that once they hit their goal weight they quietly skipped doses and stashed pens instead of quitting or telling the provider. Not ethical, but understandable when you'd be cut off after the study and could regain. Compliance would probably be better if every participant were promised some follow-up maintenance treatment after the trial ends.
